New York State Teachers Retirement System lessened its position in Heska Co. (NASDAQ:HSKA) by 20.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,503 shares of the medical research company’s stock after selling 900 shares during the period. New York State Teachers Retirement System’s holdings in Heska were worth $277,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Park West Asset Management LLC grew its position in shares of Heska by 293.3% in the 4th quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock valued at $27,885,000 after acquiring an additional 259,256 shares during the period. TimesSquare Capital Management LLC bought a new stake in shares of Heska during the 4th quarter worth about $23,831,000. Bank of New York Mellon Corp boosted its holdings in shares of Heska by 110.1% during the 4th quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock worth $16,897,000 after buying an additional 110,391 shares during the period. Redmile Group LLC bought a new stake in shares of Heska during the 4th quarter worth about $15,753,000. Finally, Ranger Investment Management L.P. boosted its holdings in shares of Heska by 436.0% during the 4th quarter. Ranger Investment Management L.P. now owns 166,583 shares of the medical research company’s stock worth $13,362,000 after buying an additional 135,505 shares during the period. 84.63% of the stock is owned by institutional investors.
Heska opened at $102.43 on Friday, according to MarketBeat. The stock has a market capitalization of $743.95 million, a price-to-earnings ratio of 56.99 and a beta of 0.68. Heska Co. has a 12-month low of $93.34 and a 12-month high of $97.67.
Several analysts recently commented on the stock. BidaskClub raised shares of Heska from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 8th. Benchmark lifted their target price on shares of Heska from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, May 7th. Canaccord Genuity reaffirmed a “buy” rating and set a $95.00 target price on shares of Heska in a report on Monday, May 7th. ValuEngine raised shares of Heska from a “sell” rating to a “hold” rating in a report on Friday, May 4th. Finally, Zacks Investment Research raised shares of Heska from a “sell” rating to a “hold” rating in a report on Thursday, May 3rd. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $100.75.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Co. (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.